Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Epilepsy

  Free Subscription


Articles published in Eur J Clin Pharmacol

Retrieve available abstracts of 13 articles:
HTML format
Text format



Single Articles


    April 2018
  1. MEI S, Feng W, Zhu L, Li X, et al
    Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
    Eur J Clin Pharmacol. 2018 Apr 17. pii: 10.1007/s00228-018-2440.
    PubMed     Text format     Abstract available


    March 2018
  2. RODRIGUES C, Chhun S, Chiron C, Dulac O, et al
    A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Eur J Clin Pharmacol. 2018 Mar 21. pii: 10.1007/s00228-018-2444.
    PubMed     Text format     Abstract available


    January 2018
  3. MORATH B, Green K, Zaradzki M, Heid J, et al
    Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report.
    Eur J Clin Pharmacol. 2018 Jan 23. pii: 10.1007/s00228-018-2417.
    PubMed     Text format    


  4. XU S, Liu L, Chen Y, Liu M, et al
    Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.
    Eur J Clin Pharmacol. 2018 Jan 16. pii: 10.1007/s00228-018-2414.
    PubMed     Text format     Abstract available


    April 2017
  5. BAFTIU A, Landmark CJ, Rusten IR, Feet SA, et al
    Erratum to: Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-A pharmacoepidemiological study and clinical implications.
    Eur J Clin Pharmacol. 2017 Apr 7. doi: 10.1007/s00228-017-2252.
    PubMed     Text format    


    March 2017
  6. SCHOEMAKER R, Wade JR, Stockis A
    Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
    Eur J Clin Pharmacol. 2017 Mar 9. doi: 10.1007/s00228-017-2230.
    PubMed     Text format     Abstract available


    February 2017
  7. PUTIGNANO D, Clavenna A, Campi R, Bortolotti A, et al
    Antiepileptic drug use in Italian children over a decade.
    Eur J Clin Pharmacol. 2017;73:241-248.
    PubMed     Text format     Abstract available


    January 2017
  8. ZHANG ZB, Ji SM, Han Y, Zang LL, et al
    Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy.
    Eur J Clin Pharmacol. 2017 Jan 7. doi: 10.1007/s00228-016-2190.
    PubMed     Text format     Abstract available


    November 2016
  9. LU Y, Fang Y, Wu X, Ma C, et al
    Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
    Eur J Clin Pharmacol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  10. BAFTIU A, Johannessen Landmark C, Rusten IR, Feet SA, et al
    Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications.
    Eur J Clin Pharmacol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  11. SIGAROUDI A, Kullak-Ublick GA, Weiler S
    Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine.
    Eur J Clin Pharmacol. 2016;72:377-8.
    PubMed     Text format    


    January 2016
  12. INOUE K, Yamamoto Y, Suzuki E, Takahashi T, et al
    Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.
    Eur J Clin Pharmacol. 2016.
    PubMed     Text format     Abstract available


  13. DJORDJEVIC N, Milovanovic DD, Radovanovic M, Radosavljevic I, et al
    CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.
    Eur J Clin Pharmacol. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Epilepsy is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: